Abstract − In anti-cancer therapies, radiotherapy and chemotherapy show a superior inhibition effect on cancer cell growth, but those are very toxic to normal tissues and organs. Particularly, drugs for neutropenia, one of chemotherapy agents, which suppress the function of bone marrow, are needed to be controlled in terms of their dosage and therapy period because of their side effect. Phellinus linteus polysaccharide (PL) has been reported to increase the number of splenocytes and bone marrow cells. PL has been shown to decrease the side effects of cyclophosphamide (CYC) treatment to the cancer patients. PL showed no effects in semisolid clonogenic assay, suggesting that PL doesn't contain substantial compounds to substitute for colony stimulating factors (CSFs). On the other hand, PL increased the expression of SCF, IL-3, GM-CSF, TPO genes. These results indicate that PL may promote the growth and proliferation of splenocytes and bone marrow cells through indirect or CSFs-dependent pathway, which may lead to a hematopoiesis.
INTRODUCTION
Cancer has been considered as one of incurable diseases, and a lot of researches have focused on curing cancers. Surgery, radiation therapy and chemotherapy have been considered as the major therapeutic modalities commonly used for the treatment of a variety of cancer patients. However, in many cases, those therapeutic modalities induce several side effects such as suppression of bone marrow functions, decrease of immune functions, abnormalities in digestive functions, and weakness (Ito et al., 1979) . Particularly, side effects of cancer therapies at bone marrow functions such as decrease of granulocytes could induce the death of the cancer patients due to the infection and septicaemia (Chauvergne et al., 1996; Pronk et al., 1995; Cascinu et al., 1995) . Therefore, therapeutic periods and the doses of the chemotherapy should be altered in order to maintain the appropriate number of neutrophils, which indicate the decrease of granulocytes. Recently, immunotherapy, inducer of differentiation and cytokines, has been attracted in cancer therapies. Especially, colony stimulating factors which regulate the growth of bone marrow cells have been employed in clinics (Clark et al., 1987; Bociek et al., 1996; Bokemeyer et al., 1996) . However, the application of the recombinant colony stimulating factors to the cancer patients has been restricted due to the side effects on the stimulation of cancer cell growth or toxicity against human being (Naglieri et al., 1998; Ridolfi et al., 1998) .
Hematopoiesis is the process which hematopoietic stem cells grow and divide into blood cells. In human, this process carried out in liver and spleen for fetus and in bone marrow for adults. In case of mice and other animals, it occurs in spleen (Dexter et al., 1997) . The generation of blood cells is known to be regulated by the direct contact of cells to one another, various hematopoietic stimulating factors and cytokines, but this process is not fully elucidated yet. The hematopoietic stimulating factors not only are essential for the growth and differentiation of blood cells, but also affect on their survival. It has been also reported that the hematopoietic cells undergo the apoptosis without hematopoietic stimulating factors (Jan et al., 1991) . The examples of hematopoietic factors are granulocyte/macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), stem cell factor (SCF), thrombopoietin (TPO), erythropoietin (EPO), interleukin-1 (IL-1), interleukin-3 (IL-3), and those factors are known to promote the growth and the differentiation of blood cells to specific types of blood cells by affecting bone marrow cells (Brugger et al., 1994 ; Arai et al., *Corresponding author Tel: +82-2-820-5597, Fax: +82-2-823-5597 E-mail: khwang@cau.ac.kr 1990).
It had been well established that many polysaccharides extracted from plants, fungi, yeast and bacteria show the anticancer activities (Takeda et al., 1969; Kao et al., 1981) . Especially, polysaccharides from Basidiomycota have been most widely studied (Chihara et al., 1969) . Those from Basidiomycota exert their anti-cancer effects as immunomodulators (Sugiura et al., 1977; Browder et al., 1983; Mansell et al., 1975) and can be used as adjuvant therapy for cancer because those polysaccharides alleviate and prevent the side effects of chemotherapy (Hirose et al., 1993) . Particularly, it has been reported that Phellinus linteus (PL) show anti-cancer effect against sarcoma 180 cancer cell line (Ikegawa et al., 1968) , decrease the growth rate of solid tumors, and increase the survival of multicancer animal models (Chung et al., 1994) . It also exerted the anti-cancer effect by increasing non-specific immune function by working at NK cells. Phellinus linteus showed strong cytotoxic effect in vivo, but weak cytotoxic effect in vitro, suggesting that Phellinus linteus exerts its anti-cancer effect by activating biological functions such as immunity and hematopoiesis (Rhee et al., 2000) . Therefore, in the present study, polysaccharides extracted from Phellinus linteus were tested for their effects on the generation of hematopoiesis stimulating factors and the growth of bone marrow and spleen in order to study their hematopoietic effects.
MATERIALS AND METHODS

Laboratory animals and materials
Male ICR mouse were purchased from HanLim laboratory and allowed to acclimatize in our facility for one week. The animals were breeding under the conditions of 24±2 o C, controlled light, and feeding without antibiotics. Phelinus linteus polysaccharide fraction was offered as 500 µg/mL. cyclophosphamide (CYC) was purchased from Sigma and diluted to 1.6 µg/mL. All reagents were diluted with 10% FBS RPMI 1640 for splenocytes and 20% FBS alpha MEM for bone marrow cells.
MTT assay
Spleen and thighbone were obtained from mouse sacrificing by enucleating. Each splenocytes and bone marrow cells were separated from these removed tissues. Cells were plated into 96 well culture plates at 1×10 6 cells per well and were treated 500 µg/mL PL, 1.6 µg/mL CYC, or 500 µg/mL PL plus 1.6 µg /mL CYC. The plates were incubated for 48 hr at 37 o C in a humidified atmosphere of 5% CO 2 . Thereafter, each well was treated with 10 µl of methylthiazololetetrazolium (5 mg/ml MTT). In order to dissolve the formazan crystals (which is result of previous step), each plate was added 10% SDS containing 0.01 N HCl. The optical density was read on a micro plate reader at 570 nm.
Semisolid clonogenic assay
Splenocytes or bone marrow cells resuspended in semisolid medium as 2×10
6 cells/ml concentration were cultured in 35 mm petri dishes. Semisolid medium was containing Iscove's modified Dulbecco's medium (IMDM) and 1% agar, 20% fetal bovine serum and 1.6 µg/mL CYC, 500 µg/mL PL, or 1.6 µg/ mL CYC plus 500 µg/mL PL according to sample group. Cell cultures were incubated for 9 days at 37 o C in a humidified atmosphere with 5% CO 2 . Colonies were counted with a microscope.
RT-PCR (reverse transcription -polymerase chain reaction)
Total RNA was extracted from 10 7 cells using Trizol reagent 
Statistical analysis
All results are given as mean±S.D. Comparison between means was made by Student's t test
RESULTS
Effect of PL on proliferation of splenocytes and bone marrow cells
To confirm whether treatment of PL increased the proliferation of hematopoietic cells, the number of splenocytes and bone
